Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX43 ± HLX07 versus docetaxel in previously treated advanced/metastatic squamous NSCLC
jRCT2021260018Phase 3Recruiting
- Sponsor
- Henlius
- Start
- Jun 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial in Pulmonary squamous cell carcinoma comparing HLX43 monotherapy, HLX43 + HLX07 combination and Docetaxel control (3 arms). Primary endpoints: Overall survival and Progression-free survival (BICR). Started Jun 2026; status: recruiting.
02
Drugs
HLX43pimurutamabdocetaxel
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on jRCT2021260018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021260018.